Skip to content

Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides

Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03952884
Enrollment
10
Registered
2019-05-16
Start date
2019-05-03
Completion date
2019-11-20
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Protein Metabolism

Keywords

Metabolism, Amino Acid Peptides, Muscle Protein Synthesis, Muscle Protein Breakdown

Brief summary

Skeletal muscle quality is an important determinant of exercise performance and overall health. It is vital for not just movement, but also metabolizing nutrients. Protein from the diet can promote muscle protein synthesis for muscle recovery and growth. More importantly, doing so shifts net protein balance positively (e.g. protein synthesis is greater than protein breakdown) and promotes greater rates of muscle protein turnover. Leucine is an amino acid required to build muscle, but it also acts as a signaling molecule informing the muscle to start protein synthesis. Before reaching skeletal muscle, dietary protein is digested into small peptides and free amino acids. Rate of absorption from the intestine to the blood stream is significantly faster for peptides compared to amino acids. As amino acid availability in the blood is a precursor for muscle protein synthesis, our objective is to determine if the different absorption rates between free amino acid and peptides influence muscle protein synthetic and breakdown rates.

Interventions

BEHAVIORALResistance Exercise

Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.

BEHAVIORALNo Resistance Exercise

Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.

DIETARY_SUPPLEMENTLeucine

Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.

DIETARY_SUPPLEMENTDileucine

Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.

Sponsors

University of Illinois at Urbana-Champaign
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Recreationally-active adults: ≥ 30 min of physical activity at moderate intensity ≥ 3 times per week * Ages: 18-35 years old * English fluency

Exclusion criteria

* Tobacco, nicotine (patch/gum) use (previous 6 mo) * Alcohol consumption \>10 drinks per week * Metabolic disorders (e.g., Metabolic Syndrome, Diabetes, thyroid diseases) * Cardiovascular disease, arrhythmias * Hypogonadism * Asthma * History of uncontrolled hypertension * Orthopedic injury/surgery (within 1 yr) * Hepatorenal, musculoskeletal, autoimmune, or neurological disease * History of neuromuscular problems * Previous participation in amino acid tracer studies * Predisposition to hypertrophic scarring or keloid formation * Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation * Consumption of thyroid, androgenic, or other medications known to affect endocrine function * Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication) * Currently pregnant

Design outcomes

Primary

MeasureTime frameDescription
Fractional Synthetic Rate of Mixed Muscle ProteinsPostabsorptive for 3.5 hours, Postprandial for 3 hours.Mixed muscle protein synthesis rates will be assessed during the 3.5hr Postabsorptive period (e.g. non-fed state) and the 3hr postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional synthetic rate from the Postabsorptive period to the postprandial period.
Fractional Synthetic Rate of Myofibrillar ProteinsPostabsorptive for 3.5 hours, Postprandial for 3 hours.Myofibrillar muscle protein synthesis rates will be assessed during the 3.5hr Postabsorptive period (e.g. non-fed state) and the 3hr postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional synthetic rate from the Postabsorptive period to the postprandial period.
Fractional Breakdown Rate of Mixed Muscle ProteinsPostprandial for 1 hourMixed muscle protein breakdown rates will be assessed during the first hour of the postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional breakdown rate for each respective experimental intervention.

Secondary

MeasureTime frameDescription
Phosphorylation of muscle anabolic signalingBaseline, immediately after ingestion of leucine/leucine peptides, and 3 hours after ingestion of leucine/leucine peptidesPhosphorylation of anabolic signaling pathways will be assessed in the fasted state and after the ingestion of the experimental interventions.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026